Appointment of Joint Broker

RNS Number : 2980G

Shield Therapeutics PLC

26 May 2017

 

Shield Therapeutics plc

("Shield" or the "Group")

Appointment of Joint Broker

London, UK, 26 May 2017: Shield Therapeutics plc (LSE:STX), a speciality pharmaceutical company focused on the development and commercialisation of late-stage pharmaceuticals that address unmet medical needs in secondary care, today announces that it has appointed Peel Hunt LLP to act as its Joint Broker with immediate effect to act alongside Liberum Capital Limited, who will continue to act as Nominated Adviser and Joint Broker to Shield.

-Ends-

For further information please contact:

Shield Therapeutics plc	[phone]
Carl Sterritt, Chief Executive Officer Joanne Estell, Chief Financial Officer
Nominated Adviser and Joint Broker	[phone]
Liberum Capital Limited
Christopher Britton/Steve Pearce
Joint Broker	+ 44 (0)20 7418 8900
Peel Hunt LLP
James Steel/Dr. Christopher Golden
Financial PR Advisor	[phone]
Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal	[e-mail]

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need.  Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until the mid-2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com

 

END

 

 

MSCDBGDULSDBGRU